Nasal Vaccine: Amid fears of a third wave of Covid-19, PM Modi announced that a vaccination campaign for adolescents between the age of 15 and 18 years would start from January 3 next year.
Prime Minister Narendra Modi during his address to the nation on Saturday (December 25, 2021), said that the nasal vaccine and the world’s first DNA-based vaccine against Covid would also start in India soon. Prime Minister made this announcement at a time when the cases of Omicron, the newest form of the global pandemic coronavirus, have started increasing rapidly in the country. Prime Minister focused more on the Nasal vaccine, let’s see what is Nasal Vaccine?
What is Nasal Vaccine?
As the name suggests, it is a nasal vaccine, so, it is given through the nose instead of a needle. It is thought to help produce an immune response at the site of infection within the respiratory tract starting from the nasal airways. This vaccine is considered best for children, as it prevents both corona infection and transmission.
Who is making nasal vaccines in India?
Bharat Biotech is developing a BBV154 nasal vaccine for children in collaboration with Washington University School of Medicine (WUSM). The Serum Institute of India (SII) is also working on it with the help of New York-based vaccine manufacturer Codagenix for the efficacy of the Intracell CoVI-VAC Covid Vaccine.
WHO’s Opinion on Nasal Vaccines?
World Health Organization (WHO) Chief Scientist Dr Soumya Swaminathan has said that the nasal vaccine can prove to be a game-changer for children. This will help immunize children against the virus. Children across the states had to bear the brunt of the lockdown as outdoor activities shut down amid the pandemic.
Let us tell you that amidst the fears of the third wave of Covid-19, PM Modi also announced that from January 3 next year, a vaccination campaign for adolescents between the age of 15 to 18 years would start.
Meanwhile, officials said the Drug Controller General of India (DCGI) has approved Bharat Biotech’s anti-Covid-19 vaccine Covaccine for emergency use for adolescents above 12 years with certain conditions. It is the second vaccine to receive regulatory approval for use among children and adolescents under 18 years of age, after Zydus Cadila, the non-needle anti-Covid-19 vaccine, Zycov-D.
Follow Seeker Times on Social media handles for quick updates.
For More updates on Covid-19, Visit WHO’s official website.